BMO Capital analyst Keith Tapper lowered the firm’s price target on Neurogene (NGNE) to $45 from $60 but keeps an Outperform rating on the shares after its Q3 results. The stock is now trading “near cash” as the company disclosed a Serious Adverse Event in its NGN-401 high dose trial and the termination of Battens program that was announced on November 11, though the management does not expect a clinical hold after conversations with FDA, acknowledging safety of low-dose, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGNE:
- Neurogene Inc. Faces Uncertainty with NGN-101 Program Amid FDA Challenges and Strategic Hurdles
- Neurogene price target lowered to $45 from $60 at BMO Capital
- Neurogene price target lowered to $46 from $72 at Baird
- Neurogene selloff on safety event an overreaction, says H.C. Wainwright
- Closing Bell Movers: Super Micro up 28% on compliance update
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue